Ardelyx, Inc. - Common Stock (ARDX)

Doubling the field reimbursement team targets prior authorization friction, a hurdle that can stall prescriptions even after demand is established.

Patient awareness push and IBSRELA sales growth both gained momentum this quarter.

Ardelyx (NASDAQ:ARDX) reported third-quarter product revenue of $125.5 million, up 19% from the prior-year period, as growth in its IBS-C treatment IBSRELA offset more modest revenue growth for dialysis-focused drug XPHOZAH. President and Chief Executive Officer Mike Raab said the company’s two fir

Ardelyx (NASDAQ:ARDX) expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia treatment XPHOZAH, executives said at a Morgan Stanley event. Chief Executive Officer Mike Raab sa

Record revenue masks payer headwinds forcing IBSRELA guidance cuts.

Ardelyx (NASDAQ:ARDX) reported second-quarter product revenue of $118 million, up 31% from a year earlier and representing the company’s largest quarterly revenue total to date. The company lowered its 2026 revenue outlook for IBSRELA while maintaining its forecast for XPHOZAH, citing increased paye

This biotech specializing in gastrointestinal and cardiorenal therapies reported a notable insider sale following strong 1-year returns.

Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability. Chief Financia

Ardelyx (ARDX) Q1 2026 Earnings Transcript

This biotech innovator in gastrointestinal and kidney therapies reported a notable insider sale amid routine portfolio adjustments.

Ardelyx is coming off a strong Q4 earnings report for fiscal year 2025. But how is the stock performing?

On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.

Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10.

The company reported no earnings for the fourth quarter, compared to an analyst estimate of $0.01 per share.

The company said it made significant commercial progress in 2025, generating approximately $378 million in product revenue.

Ardelyx (ARDX) Q3 2025 Earnings Call Transcript

The investment company displayed confidence in Teladoc's growth potential by expanding its holdings in the stock.